Clinical validation of MsdiagTM test for predicting Multiple Sclerosis activity.

P. Villoslada , J. Sepulcre , B. Duque , J. Goni , B. Fernandez , C. Lyonnais , M. Geffard (1, 2)

1 LPIOM - Laboratoire de physique des interactions ondes matières
2 IMS - Laboratoire de l'intégration, du matériau au système

Background: The MSdiag™ test assess a set of 34 circulating antibodies directed against fatty acids, acetylcholine-like, azelaic acid, malondialdehyde residue, NO-modified amino-acids and enterobacterial antigens by ELISA (M Geffard. J Neuroimmunol 1996). These set of antibodies have been described to be differentially expressed in different MS disease course. Objective: To assess the association between MSdiag™ test and disease activity in a cohort of MS patients. Methods: We study a cohort of 61 MS patients with early to medium disease duration (22 CIS, 28 RRMS, 5 SPMS, 6 PPMS), low-medium disability (EDSS: 2.0 (0 – 7.0); MSSS: 4.6; MSFC: 0.64 +1.68) and a relapse rate in the 2 previous years of 1.43. Patients were followed every 3 months for 2 years. The MSdiag test was performed every 3 months in a blind manner. A 3D MRI with gadolinium study was performed at baseline. Results: Two patients were lost for follow-up. Relapse rate during the follow-up was 1.23, and 26 patients were relapse-free. The increase in the EDSS by the end of the study was 0.41 + 0.7 and 12 patients had confirmed progression (1 point increase in the EDSS confirmed at 6 months). Twelve CIS patients converted to RRMS and 5 RRMS patients developed SPMS. We found moderate correlation between MSdiag™ subtest directed against enterobaterial antigens and disability (EDSS and MSFC) at the end of the study: 1) the rise of antibodies 5M, 16M, 12M, 19M and 5A was associated with disease progression; 2) we found a moderate correlation between 16M and 5M antibody titers and EDSS change (confirmed at 6 months). The rise of antibody 16M was associated with the conversion from CIS to RRMS; and the increase of antibody 17A titers was associated with being non relapse-free by the end of the study. None of the tests correlated with the number of relapses in the follow-up, disease subtype at baseline, response to immunomodulatory therapy or gadolinium enhancing lesions. Conclusions: The assessment of several antibodies in the MSdiag™ test might be useful to identify patients with active disease

Domaines: Biophysique; Toxicologie

P. Villoslada, J. Sepulcre, B. Duque, J. Goni, B. Fernandez, et al.. Clinical validation of MsdiagTM test for predicting Multiple Sclerosis activity.. 22th Congress ECTRIMS, Sep 2006, Madrid, Spain. ⟨hal-00162058⟩